İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2023

What We Learned about COVID-19 So Far? Notes from Underground

AVES YAYINCILIK A.Ş.

YÖKSİS OpenAlex Açık erişim · diamond Atıf 9 Yüzdelik 42.2% FWCI 0.17
Yıl
2023
ISSN
3258-4236
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

The novel coronavirus pandemic poses a major global threat to public health. Our knowledge concerning every aspect of COVID-19 is evolving rapidly, given the increasing data from all over the world. In this narrative review, the Turkish Thoracic Society Early Career Taskforce members aimed to provide a summary on recent literature regarding epidemiology, clinical findings, diagnosis, treatment, prevention, and control of COVID-19. Studies revealed that the genetic sequence of the novel coronavirus showed significant identity to SARS-CoV and MERS-CoV. Angiotensin-converting enzyme 2 receptor is an important target of the SARS-CoV-2 while entering an organism. Smokers were more likely to develop the disease and have a higher risk for ICU admission. The mean incubation period was 6.4 days, whereas asymptomatic transmission was reported up to 25 days after infection. Fever and cough were the most common symptoms, and cardiovascular diseases and hypertension were reported to be the most common comorbidities among patients. Clinical manifestations range from asymptomatic and mild disease to severe acute respiratory distress syndrome. Several patients showed typical symptoms and radiological changes with negative RT-PCR but positive IgG and IgM antibodies. Although radiological findings may vary, bilateral, peripherally distributed, ground-glass opacities were typical of COVID-19. Poor prognosis was associated with older age, higher Sequential Organ Failure Assessment score, and high D-dimer level. Chloroquine was found to be effective in reducing viral replication in vitro. Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission, treatment, and prevention of COVID-19.

Konular

  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19

Birincil konu COVID-19 Clinical Research Studies

Yazarlar

  1. FATMA TOKGÖZ AKYIL
  2. DİLEK KARADOĞAN
  3. CANAN GÜNDÜZ GÜRKAN
  4. AYCAN YÜKSEL
  5. HÜSEYİN ARIKAN
  6. TUĞBA ŞİŞMANLAR EYÜBOĞLU
  7. NAGEHAN EMİRALİOĞLU ORDUKAYA
  8. TUĞBA RAMASLI GÜRSOY
  9. İREM ŞERİFOĞLU RAHATLI
  10. ZEHRA NUR TÖREYİN
  11. FERİDE MARIM
  12. BİLGE YILMAZ KARA
  13. HİLAL ÖZAKINCI
  14. ELİF DEVELİ
  15. SELİN ÇAKMAKCI KARAKAYA
  16. TUBA ÇİFTÇİ KÜSBECİ
  17. OĞUZ KARCIOĞLU
  18. MERVE ERÇELİK KONCAK
  19. BERRİN ER
  20. ÖZLEM ATAOĞLU DÜZCE ÜNİVERSİTESİ
  21. DEMET POLAT YULUĞ MERSİN ÜNİVERSİTESİ
  22. İLKNUR KAYA
  23. TUĞBA ASLI ÖNYILMAZ
  24. ASENA ÇEKEN
  25. DENİZ KIZILIRMAK
  26. ASLIHAN BANU ER
  27. MUKADDES KILINÇ
  28. FATMA ESRA GÜNAYDIN
  29. SELÇUK GÜRZ ONDOKUZ MAYIS ÜNİVERSİTESİ
  30. SELEN KARAOĞLANOĞLU
  31. HATİCE SELMA ÇELİKYAY
  32. DORINA ESENDAGLI
  33. HÜSEYİN TOPTAY
  34. ÜMRAN ÖZDEN SERTÇELİK
  35. METİN AKGÜN